Aquestive Therapeutics
AQST
116 hedge funds and large institutions have $158M invested in Aquestive Therapeutics in 2025 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 53 increasing their positions, 26 reducing their positions, and 19 closing their positions.
104% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 26
21% more capital invested
Capital invested by funds: $131M → $158M (+$26.9M)
3.19% more ownership
Funds ownership: 44.76% → 47.95% (+3.2%)
4% less funds holding
Funds holding: 121 → 116 (-5)
21% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 19
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
38% less call options, than puts
Call options by funds: $729K | Put options by funds: $1.17M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$7.81M |
| 2 |
SCM
Sio Capital Management
New York
|
+$1.59M |
| 3 |
BlackRock
New York
|
+$1.55M |
| 4 |
EAM
Everstar Asset Management
Mooresville,
North Carolina
|
+$1.03M |
| 5 |
PFCS
Pale Fire Capital SE
Prague,
Czech Republic
|
+$977K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$4.41M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$3.04M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$882K |
| 4 |
Goldman Sachs
New York
|
-$844K |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$549K |
AQST Hedge Fund Activity: Q2 2025 in Review
116 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q2 2025, worth a combined $158M — up 21% from $131M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of AQST and 15 opened new positions — a net loss of 4 holders — while 26 trimmed existing stakes and 53 added.
The largest buyer was Millennium Management, adding an estimated $7.81M. The largest seller was Perceptive Advisors, cutting an estimated $4.41M.
- 116 institutional investors held Aquestive Therapeutics (AQST) as of Q2 2025, down from 121 in Q1 2025.
- Funds reported $158M of Aquestive Therapeutics stock for Q2 2025, up 21% quarter-over-quarter.
- 15 funds opened new Aquestive Therapeutics positions in Q2 2025 and 19 closed out, a net change of -4 holders.
- The largest Aquestive Therapeutics buyer in Q2 2025 was Millennium Management, an estimated $7.81M added.
- The largest Aquestive Therapeutics seller in Q2 2025 was Perceptive Advisors, an estimated $4.41M sold.
Based on aggregated 13F filings for Q2 2025.